{"groups":[{"id":"FG000","title":"Sorafenib + Lenalidomide + Dexamethasone"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"This was a phase I/II trial. A total of 13 participants were accrued, all to the phase I portion. This trial was terminated due to study design and toxicity during the phase I; therefore, the phase II portion will never open. No results from the phase II portion are available.","recruitmentDetails":"Thirteen (13) participants were recruited at Mayo Clinic between August 2008 and March 2010."}